Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06260891 · ClinicalTrials.gov registry record · Phase 2

Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

A Phase 2 study of Sickle Cell Disease, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 2
Development phase
34
Enrollment target
6
Study locations

NCT06260891 is a Phase 2 study of Sickle Cell Disease that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 34 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06260891, a Phase 2 study of Sickle Cell Disease, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
6
Study locations

Study Summary

The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most responsive to zinc supplementation, and what is the maximum tolerated zinc dose that induces the desired changes in biomarkers of bone turnover? Participants will be recruited from 6 American Society Hematology Research Collaborative SCD Centers. Eligible SCD subjects will be invited to participate in the 16-week study, involving 2 baseline blood draws 4 weeks apart, followed by a 12-week zinc intervention. The findings from this study will be used to determine the dosage of zinc to be used in a larger, future study on the long term impact of zinc supplementation on bone health in SCD-SS.

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG 25 mg/day zinc
  • DRUG 40 mg/day zinc

Study Locations (6)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Thomas Jefferson University Hospital - Philadelphia

California

  • UCSF Benioff Children's Hospital Oakland - Oakland

North Carolina

  • Duke University Medical Center - Durham

Ohio

  • Cincinnati Children's Hospital - Cincinnati

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2026-02-14
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

University of California, San Francisco

1,713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06260891

The ClinicalTrials.gov registry entry for NCT06260891 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (88% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which 25 mg/day zinc is the first listed.

NCT06260891 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06260891 about?

NCT06260891 is a clinical study titled "Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial". The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most re...

What is the current status of trial NCT06260891?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2026-02-14. Estimated completion is 2027-12-31.

What conditions does trial NCT06260891 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT06260891?

The interventions under investigation include: 25 mg/day zinc (DRUG), 40 mg/day zinc (DRUG).

Who is sponsoring clinical trial NCT06260891?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06260891 being conducted?

This trial has 6 study locations across California, North Carolina, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.